Organization
University Hospitals Seidman Cancer Center
33 abstracts
Abstract
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,
Abstract
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.Org: ECOG-ACRIN Biostatistics Center, University Hospitals Seidman Cancer Center, University of Miami Sylvester Cancer Center, Ohio State University Comprehensive Cancer Center, Temple University Health System,
Abstract
Prospective iterative data visualization (DV) study to enhance health literacy in prostate cancer (PC).Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, ZERO Prostate Cancer, Alexandria, VA,
Abstract
Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial.Org: Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
Out-of-pocket cost modeling of adjuvant radiation therapy duration in standard-of-care treatment of glioblastoma across Medicaid and Medicare plans.Org: Case Western Reserve University School of Medicine, Department of Radiation Oncology, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center,
Abstract
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.Org: START Midwest, Grand Rapids, MI, Memorial Sloan Kettering Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Yale School of Medicine, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Accuracy of medical oncology prognosis for patients with metastatic cancer evaluated for enrollment onto an ongoing randomized clinical trial.Org: University Hospitals Seidman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Case Western Reserve University School of Medicine,
Abstract
Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function.Org: Mayo Clinic, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center,
Abstract
A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,
Abstract
Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: Real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area.Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine,
Abstract
Influence of family caregivers on clinical trial decisions: Results from a qualitative study.Org: Case Western Reserve University School of Medicine, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University Hospitals Seidman Cancer Center, School of Nursing, University of Alabama at Birmingham, Birmingham, AL,
Abstract
Cisplatin-vinblastine-temozolomide regimen for patients with relapsed-refractory melanoma who are ineligible for clinical trials: A tertiary care center experience.Org: University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center Rehabilitation Services, University Hospitals Cleveland Medical Center, University Hospitals Sussex NHS Foundation Trust,
Abstract
The association between osimertinib and nutritional deficiency among patients with non-small cell lung cancer.Org: Unity Hospital, Rochester Regional Health System, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Disparities in diagnosis and access to care in patients with young-onset rectal cancers in northeast Ohio.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University Hospitals Cleveland Medical Center,
Abstract
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.Org: Dana-Farber Cancer Institute, Genentech, F. Hoffmann-La Roche Ltd, University Hospitals Seidman Cancer Center, Massachusetts General Hospital,
Abstract
Assessing the marginal costs of radiation therapy and antiestrogen therapy for post-lumpectomy, early-stage breast cancer across Medicaid and Medicare plans.Org: Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Emory University School of Medicine, University Hospitals Seidman Cancer Center,
Abstract
The effect of various social determinants of health on overall survival in the SCLC population.Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine,
Abstract
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).Org: Institut Gustave Roussy, The Royal Marsden Hospital (Surrey), London, United Kingdom, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Hospitals Seidman Cancer Center, START San Antonio,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.Org: Guardant Health, Inc., Mayo Clinic Florida, Mayo Clinic, Emory University, Atlanta, GA, USA, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Oregon Health & Science University, Knight Cancer Institute,
Abstract
Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): Updated individual patient data meta-analyses from the MARCAP consortium.Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, University of California Los Angeles, Alfred Health Radiation Oncology,
Abstract
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).Org: UT Health San Antonio, MD Anderson Cancer Center, Institut Curie, Saint Cloud, France, Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, University Hospitals Seidman Cancer Center, Jean Perrin Cancer Centre,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
The impact of patient age on palliative care utilization and end-of-life outcomes among metastatic breast cancer patients.Org: University Hospitals Sussex NHS Foundation Trust, Department of Medicine, Icahn School of Medicine at Mount Sinai, Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology, Case Western Reserve University School of Medicine,
Abstract
Navigator utilization rates in breast cancer patients by race in a comprehensive cancer center.Org: University Hospital Seidman Cancer Center, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Bon Secours St Francis Health System, University General Hospital Attikon, University Hospitals Seidman Cancer Center, CHU Angers,
Abstract
Impact of free hospital-provided rideshare service on radiation therapy completion rates: A matched cohort analysis.Org: University Hospitals Seidman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Cleveland, OH, Case Western Reserve University School of Medicine, Department of Population Quantitative Health Sciences,
Abstract
Real world genomics in metastatic urothelial carcinoma (mUC).Org: University Hospitals Seidman Cancer Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Department of Medical Genetics, Cleveland, OH, Cancer Informatics,
Abstract
The current state and future of neoadjuvants in resectable melanoma: Review of phase II/III studies conducted between 2018-2022.Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center,
Abstract
Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.Org: University Hospitals Cleveland Medical Center, Cleveland, OH, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center,
Abstract
Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI).Org: Winship Cancer Institute of Emory University, Caris Life Sciences, Irving, TX, Medical Oncology/ TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, RI Hosp Brown Univ, Department of Medicine, Emory University School of Medicine,
Abstract
Morbidity of Single-Fraction Spine Radiosurgery for Metastatic Disease.Org: Johns Hopkins Hospital, University Hospitals Seidman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Case Western Reserve University School of Medicine,